A BILL 
To amend the Controlled Substances Act to list fentanyl- 
related substances as schedule I controlled substances. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Stopping Illicit Traf-
4
ficking Act of 2021’’ or the ‘‘SIFT Act of 2021’’. 
5
06:23 May 18, 2021
H2041
2 
•HR 2041 IH
SEC. 2. FENTANYL-RELATED SUBSTANCES. 
1
Section 202(c) of the Controlled Substances Act (21 
2
U.S.C. 812) is amended— 
3
(1) by adding at the end of subsection (b) of 
4
Schedule I the following: 
5
‘‘(23) Isobutyryl fentanyl. 
6
‘‘(24) Para-Methoxybutyrylfentanyl. 
7
‘‘(25) Valeryl fentanyl. 
8
‘‘(26) Cyclopentyl fentanyl. 
9
‘‘(27) Para-Chloroisobutyryl fentanyl.’’; and 
10
(2) by adding at the end of Schedule I the fol-
11
lowing: 
12
‘‘(e)(1) Unless specifically exempted or unless listed 
13
in another schedule, any material, compound, mixture, or 
14
preparation which contains any quantity of fentanyl-re-
15
lated substances, or which contains their salts, isomers, 
16
and salts of isomers whenever the existence of such salts, 
17
isomers, and salts of isomers is possible within the specific 
18
chemical designation. 
19
‘‘(2) In paragraph (1), the term ‘fentanyl-related sub-
20
stances’ includes the following: 
21
‘‘(A) Any substance that is structurally related 
22
to fentanyl by one or more of the following modifica-
23
tions: 
24
‘‘(i) By replacement of the phenyl portion 
25
of the phenethyl group by any monocycle, 
26
06:23 May 18, 2021
H2041
3 
•HR 2041 IH
whether or not further substituted in or on the 
1
monocycle. 
2
‘‘(ii) By substitution in or on the phenethyl 
3
group with alkyl, alkenyl, alkoxy, hydroxy, halo, 
4
haloalkyl, amino or nitro groups. 
5
‘‘(iii) By substitution in or on the piper-
6
idine ring with alkyl, alkenyl, alkoxy, ester, 
7
ether, hydroxy, halo, haloalkyl, amino or nitro 
8
groups. 
9
‘‘(iv) By replacement of the aniline ring 
10
with any aromatic monocycle whether or not 
11
further substituted in or on the aromatic mono-
12
cycle. 
13
‘‘(v) By replacement of the N-propionyl 
14
group by another acyl group. 
15
‘‘(B) 4′-Methyl acetyl fentanyl. 
16
‘‘(C) Crotonyl fentanyl. 
17
‘‘(D) 2′-Fluoro ortho-fluorofentanyl. 
18
‘‘(E) Ortho-Methyl acetylfentanyl. 
19
‘‘(F) Thiofuranyl fentanyl. 
20
‘‘(G) Ortho-Fluorobutyryl fentanyl. 
21
‘‘(H) Ortho-Fluoroacryl fentanyl. 
22
‘‘(I) Beta-Methyl fentanyl. 
23
‘‘(J) Phenyl fentanyl. 
24
‘‘(K) Para-Methylfentanyl. 
25
06:23 May 18, 2021
H2041
4 
•HR 2041 IH
‘‘(L) Beta′-Phenyl fentanyl. 
1
‘‘(M) Benzodioxole fentanyl.’’. 
2
SEC. 3. REMOVAL FROM SCHEDULE I(e) OF FENTANYL-RE-
3
LATED SUBSTANCES. 
4
Section 201 of the Controlled Substances Act (21 
5
U.S.C. 811) is amended by adding at the end the following 
6
new subsection: 
7
‘‘(k)(1) If the Secretary finds, based on the factors 
8
specified in paragraph (4), that a substance listed in 
9
schedule I(e) has no potential for abuse, the Secretary 
10
shall— 
11
‘‘(A) notify the Attorney General at least 90 
12
days prior to submitting an evaluation scientific and 
13
medical evaluation of that substance supporting that 
14
conclusion; and 
15
‘‘(B) submit to the Attorney General such eval-
16
uation and conclusion that— 
17
‘‘(i) is in writing; and 
18
‘‘(ii) includes the bases for such conclu-
19
sion. 
20
‘‘(2) Not later than 90 days after the receipt of such 
21
evaluation and conclusion, the Attorney General shall 
22
issue an order removing such substance from the schedule. 
23
‘‘(3)(A) If the Secretary finds, based on the factors 
24
specified in paragraph (4), that a substance listed in 
25
06:23 May 18, 2021
H2041
5 
•HR 2041 IH
schedule I(e) does not meet the requirements for inclusion 
1
in that schedule, and that the substance has a low poten-
2
tial for abuse, the Secretary shall submit to the Attorney 
3
General a scientific and medical evaluation of that sub-
4
stance supporting those conclusions that is in writing and 
5
that includes the bases for that conclusion. 
6
‘‘(B) Within 180 days of receipt of such evaluation 
7
and conclusion, the Attorney General shall— 
8
‘‘(i) issue an order removing such substance 
9
from scheduling for research purposes only, or 
10
‘‘(ii) notify the Secretary in writing that the At-
11
torney General declines to issue such an order. 
12
‘‘(4) In making the evaluation and conclusion de-
13
scribed in paragraph (1) or (3), the Secretary— 
14
‘‘(A) shall consider the factors specified in 
15
paragraphs (1), (2), (3), and (6) of subsection (c) 
16
and any information submitted to the Attorney Gen-
17
eral under paragraph (1) of this subsection; and 
18
‘‘(B) may also consider factors specified in 
19
paragraphs (4), (5), and (7) of subsection (c) if the 
20
Secretary finds that reliable evidence exists with re-
21
spect to such factors. 
22
‘‘(5) Nothing in this subsection shall preclude the At-
23
torney General from transferring a substance listed in 
24
schedule I to another schedule, or removing such sub-
25
06:23 May 18, 2021
H2041
6 
•HR 2041 IH
stance entirely from the schedules, pursuant to other pro-
1
visions of this section or section 202. 
2
‘‘(6) A substance removed from schedule I(e) pursu-
3
ant to paragraph (1) or (3) may, at any time, be controlled 
4
pursuant to the other provisions of this section or section 
5
202 without regard to that removal.’’. 
6
SEC. 4. CLARIFICATION OF CERTAIN REGISTRATION RE-
7
QUIREMENTS RELATED TO RESEARCH. 
8
(a) EXCEPTION FOR AGENTS OR EMPLOYEES OF 
9
REGISTERED RESEARCHERS.—Section 302(c)(1) of the 
10
Controlled Substances Act (21 U.S.C. 822(c)(1)) is 
11
amended by striking ‘‘or dispenser’’ and inserting ‘‘dis-
12
penser, or researcher’’. 
13
(b) CONFORMING AMENDMENT.—Section 102(3) of 
14
the Controlled Substances Act (21 U.S.C. 802(3)) is 
15
amended by striking ‘‘or dispenser’’ and inserting ‘‘dis-
16
penser, or researcher.’’ 
17
(c) SINGLE REGISTRATION FOR CONTIGUOUS RE-
18
SEARCH SITES.—Section 302(e) of the Controlled Sub-
19
stances Act (21 U.S.C. 822(e)) is amended by adding at 
20
the end the following new paragraph: 
21
‘‘(3) Notwithstanding paragraph (1), a person 
22
registered to conduct research with a controlled sub-
23
stance under section 303(f) may conduct such re-
24
search under a single registration if such research 
25
06:23 May 18, 2021
H2041
7 
•HR 2041 IH
occurs exclusively on a single, contiguous campus 
1
and the registrant notifies the Attorney General in 
2
writing of all sites on the campus where the research 
3
will be conducted or where the controlled substance 
4
will be stored or administered. If the registrant 
5
seeks to conduct such research at additional sites, 
6
the registrant shall submit a new notification before 
7
conducting such research at any such additional 
8
sites.’’. 
9
(d) NEW INSPECTION NOT REQUIRED IN CERTAIN 
10
SITUATIONS.—Section 303(f) of the Controlled Sub-
11
stances Act (21 U.S.C. 823(f)) is amended— 
12
(1) by redesignating paragraphs (1) through 
13
(5) as subparagraphs (A) through (E), respectively, 
14
and by moving the margins of such subparagraphs 
15
(as so redesignated) two ems to the right; 
16
(2) by striking ‘‘(f) The’’ and inserting ‘‘(f)(1) 
17
The’’; and 
18
(3) by adding at the end the following new 
19
paragraph: 
20
‘‘(2)(A) If a person is registered to conduct research 
21
with a controlled substance and applies to be registered, 
22
or to modify a registration to conduct research with a sec-
23
ond controlled substance that is in the same schedule or 
24
in a schedule with a higher numerical designation, a new 
25
06:23 May 18, 2021
H2041
8 
•HR 2041 IH
inspection by the Attorney General of the registered loca-
1
tion is not required. 
2
‘‘(B) Nothing in this paragraph shall prohibit the At-
3
torney General from conducting any inspection if the At-
4
torney General determines such an inspection is nec-
5
essary.’’. 
6
(e) CONTINUATION OF RESEARCH ON NEWLY ADDED 
7
SUBSTANCES; AUTHORITY TO CONDUCT RESEARCH WITH 
8
OTHER SUBSTANCES.—Section 302 of the Controlled 
9
Substances Act (21 U.S.C. 822), as amended by sub-
10
sections (a) and (c), is further amended by adding at the 
11
end the following new subsection: 
12
‘‘(h)(1) In the case of a person who is conducting 
13
research on a substance at the time the substance is added 
14
to schedule I and who is already registered to conduct re-
15
search with another controlled substance in schedule I or 
16
II, the person— 
17
‘‘(A) within 30 days of the scheduling of such 
18
substance, shall submit a completed application for 
19
registration or modification of the existing registra-
20
tion of such person, to conduct research on such 
21
substance, in accordance with the regulations issued 
22
by the Attorney General; and 
23
06:23 May 18, 2021
H2041
9 
•HR 2041 IH
‘‘(B) notwithstanding subsections (a) and (b), 
1
may continue to conduct the research on such sub-
2
stance until the date on which— 
3
‘‘(i) the application referred to in subpara-
4
graph (A) is withdrawn by the applicant; or 
5
‘‘(ii) the Attorney General serves on the 
6
applicant an order to show cause proposing the 
7
denial of the application pursuant to section 
8
304(c). 
9
‘‘(2) If the Attorney General serves an order to show 
10
cause under paragraph (1)(B) and the applicant requests 
11
a hearing, such hearing shall be held— 
12
‘‘(A) on an expedited basis; and 
13
‘‘(B) not later than 45 days after the request 
14
is made, or such a later time as requested by the ap-
15
plicant. 
16
‘‘(3)(A) A person who is registered to conduct re-
17
search with a controlled substance in schedule I may, not-
18
withstanding subsections (a) and (b), conduct research 
19
with another controlled substance in schedule I, if each 
20
of following conditions are met: 
21
‘‘(i) The person has applied for a modification 
22
of the person’s registration to authorize research 
23
with such other controlled substance in accordance 
24
with the regulations issued by the Attorney General. 
25
06:23 May 18, 2021
H2041
10 
•HR 2041 IH
‘‘(ii) The Attorney General has obtained 
1
verification from the Secretary that the research 
2
protocol submitted with the application is meri-
3
torious. 
4
‘‘(iii) The Attorney General has determined 
5
under subparagraph (B) that the conduct of such re-
6
search is consistent with United States obligations 
7
under the Single Convention on Narcotic Drugs, 
8
1961. 
9
‘‘(B) Not later than 30 days after receiving an appli-
10
cation under clause (i), the Attorney General shall deter-
11
mine whether the conduct of research that is the subject 
12
of the application is consistent with United States obliga-
13
tions under the Single Convention on Narcotic Drugs, 
14
1961. 
15
‘‘(C) Nothing in this section shall be construed to 
16
alter the authority of the Attorney General to initiate pro-
17
ceedings to deny, suspend, or revoke any registration in 
18
accordance with sections 303 and 304.’’. 
19
(f) TREATMENT OF CERTAIN ACTIVITIES AS COINCI-
20
DENT TO RESEARCH.—Section 302 of the Controlled Sub-
21
stances Act (21 U.S.C. 822), as amended by subsections 
22
(a), (c), and (e), is further amended by adding at the end 
23
the following new subsection: 
24
06:23 May 18, 2021
H2041
11 
•HR 2041 IH
‘‘(i) A person who is registered to perform research 
1
with a controlled substance (other than marihuana) under 
2
this title may, without being required to registered to man-
3
ufacture such substance, using small quantities of such 
4
substance, perform the following activities: 
5
‘‘(1) Processing the substance to create ex-
6
tracts, tinctures, oils, solutions, derivatives, or other 
7
forms of the substance consistent with the approved 
8
research protocol. 
9
‘‘(2) Dosage form development for the purpose 
10
of satisfying requirements with respect to the sub-
11
mission of an investigational new drug application 
12
under section 505(i) of the Federal Food, Drug, and 
13
Cosmetic Act.’’. 
14
SEC. 5. REVIEW OF RESEARCH REGISTRATION PROCESS. 
15
(a) REVIEW.—Not later than one year after the date 
16
of the enactment of this section, the Attorney General and 
17
the Secretary of Health and Human Services shall jointly 
18
conduct a review of the processes used to register or mod-
19
ify a registration to conduct research with controlled sub-
20
stances under the Controlled Substances Act (21 U.S.C. 
21
801 et seq.), including— 
22
(1) an evaluation of the impacts of the amend-
23
ments made by this Act on the risk of the diversion 
24
06:23 May 18, 2021
H2041
12 
•HR 2041 IH
of controlled substances used in research and related 
1
public safety considerations; and 
2
(2) an identification of opportunities to reduce 
3
any unnecessary burden on persons seeking registra-
4
tion, potential redundancies, and inefficiencies in 
5
such processes, including— 
6
(A) the process for obtaining a registration 
7
under section 303 of the Controlled Substances 
8
Act (21 U.S.C. 823); and 
9
(B) the process by which the Secretary re-
10
views research protocols submitted with respect 
11
to such registration. 
12
(b) GUIDANCE.—Not later than 60 days after con-
13
cluding the review described in subsection (a), the Attor-
14
ney General and the Secretary shall, as appropriate, joint-
15
ly issue guidance to registrants and potential registrants 
16
clarifying the process for registration. 
17
Æ 
06:23 May 18, 2021
H2041
